

Dated: December 19, 2025

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules Life Sciences facility completed the FDA inspection
Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Mam,

Please be informed that the wholly owned subsidiary of the Company, Granules Life Sciences Private Limited (GLS), located in Hyderabad (FEI: 3030495702), has completed a Good Manufacturing Practices (GMP) and Prior Approval Inspection by the U.S. Food and Drug Administration (FDA).

The inspection conducted from 15th to 19th December 2025 has concluded with five observations related to procedural requirements. None of these observations are associated with data integrity or product safety.

Granules India is committed to addressing the observations promptly and will submit its response to the USFDA within the stipulated timeframe.

Granules Life Sciences Private Limited is engaged in the manufacturing of PFI & Finished Dosages.

This is for your information and dissemination to the members of the exchange.

Thanking You.
For GRANULES INDIA LIMITED

CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)

REGISTERED OFFICE

Granules India Limited
CIN: L24110TG1991PLC012471
15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India
Contact Us: Tel: +91-40-69043500 |Fax: +91-40-23115145| mail@granulesindia.com